Original article Clinical significance of determining sST2 in the blood of patients with cardiac sarcoidosis

Marina V. Lebedeva , Leonid A. Strizhakov , Vladimir D. Beketov , Marina V. Taranova

For citation:

Abstract

The results of a pilot study of the serum marker of cardiac damage sST2 in patients with chronic generalized sarcoidosis are presented. Correlations between the activity of sarcoidosis, sST2 levels and the risk of developing heart failure have been demonstrated.
Keywords: sST2, sarcoidosis, cardiac sarcoidosis, heart failure.

References

1. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и др. Саркоидоз: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(6):806-33. DOI: 10.18093/0869-0189-2022-32-6-806-833

Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Sarcoidosis: federal clinical guidelines for diagnosis and treatment. Pulmonologiya. 2022;32(6):806-33. DOI: 10.18093/0869-0189-2022-32-6-806-833 (in Russian).

2. Rossides M, Darlington P, Kullberg S, Arkema EV. Sarcoidosis: Epidemiology and clinical insights. J Intern Med. 2023;293(6):668-80. DOI: 10.1111/joim.13629

3. Цветкова О.А., Абдуллаева Г.Б., Воронкова О.О. и др. Саркоидоз с поражением сердца и моноклональной гаммапатией. Кардиология. 2020;60(4):151-6. DOI: 10.18087/cardio.2020.4.n712

Tsvetkova О.А., Abdullaeva G.B., Voronkova O.O. et al. Sarcoidosis With Cardiac Involvement and Monoclonal Gammopathy. Kardiologiia. 2020;60(4):151-6 (in Russian).

4. Dae-Won Sohn, Jun-Bean Park. Cardiac sarcoidosis. Heart. 2023;109(15):1132-8. DOI: 10.1136/heartjnl-2022-321379

5. Драпкина О.М., Концевая А.В., Кравченко А.Я. и др. Биомаркеры ST2 и интерлейкин 33 в оценке кардиального воспаления, фиброза и прогноза пациентов с хронической сердечной недостаточностью. Российский кардиологический журнал. 2021;26(3S):4530. DOI: 10.15829/1560-4071-2021-4530

Drapkina O.M., Kontsevaya A.V., Kravchenko A.Ya. et al. Biomarkers ST2 and interleukin 33 for assessing the severity of cardiac inflammation and fibrosis in patients with chronic heart failure. Russian Journal of Cardiology. 2021;26(3S):4530. DOI: 10.15829/1560-4071-2021-4530 (in Russian).

6. Копьева К.В., Гракова Е.В., Тепляков А.Т. Новые маркеры сердечной недостаточности: значение для диагностики и прогнозирования NT-proBNP и интерлейкиновых рецепторов – членов семейства ST2. Комплексные проблемы сердечно-сосудистых заболеваний. 2018;7(1):94-101. DOI: 10.17802/2306-1278-2018-7-1-94-101

Kopeva K.V., Grakova E.V., Teplyakov A.T. New biomarkers of heart failure: diagnostic and prognostic value of NT-proBNP and interleukin receptor family member ST2. Complex Issues of Cardiovascular Diseases. 2018;7(1):94-101. DOI: 10.17802/2306-1278-2018-7-1-94-101 (in Russian).

7. Pascual-Figal D, Perez-Martinez M, Asensio-Lopez M et al. Pulmonary Production of Soluble ST2 in Heart Failure. Circulation: Heart Failure. 2018;11(12):e005488. DOI: 10.1161/CIRCHEARTFAILURE.118.005488

8. Gruson D, Lepoutre T, Ahn SA, Rousseau MF. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol. 2014;172(1):e250-2. DOI: 10.1016/j.ijcard.2013.12.101

9. Самсонова М.В., Черняев А.Л. Гранулематозные заболевания легких. Пульмонология. 2017;27(2):250-61. DOI: 10.18093/086930 189320173273232503261

Samsonova M.V., Chernyaev A.L. Granulomatous lung diseases. Pulmonology. 2017;27(2):250-61. DOI: 10.18093/0869301893201732 73232503261 (in Russian).

10. Januzzi Jr JL. ST2 as a cardiovascular risk biomarker: from the bench to the bedside. J Cardiovasc Transl Res. 2013;6(4):493-500. DOI: 10.1007/s12265-013-9459-y

11. Муксинова М.Д., Нарусов О.Ю., Скворцов А.А. Натрийуретические пептиды и растворимый ST2-рецептор: роль в диагностике, стратификации риска и лечении больных с хронической сердечной недостаточностью. Кардиологический вестник. 2019;(4):22-33. DOI: 10.36396/MS.2019.15.4.003

Muksinova M.D., Narusov O.Yu., Skvortsov A.A. Natriuretic peptides and soluble ST2 receptor: role in the diagnosis, risk stratification and treatment of patients with chronic heart failure. Cardiology bulletin. 2019;(4):22-33. DOI: 10.36396/MS.2019.15.4.003 (in Russian).

12. Алиева А.М., Резник Е.В., Гасанова Э.Т. и др. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018;8(5):333-45. DOI: 10.20514/2226-6704-2018-8-5-333-345

Alieva A.M., Reznik E.V., Gasanova E.T., Zbanov I.V., Nikitin I.G. Clinical significance of determining blood biomarkers in patients with chronic heart failure. Archive of Internal Medicine. 2018;8(5):333-45. DOI: 10.20514/2226-6704-2018-8-5-333-345 (in Russian).

13. Lupón J, Gaggin HK, de Antonio M et al. Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score. Int J Cardiol. 2015;184:337-43. DOI: 10.1016/j.ijcard.2015.02.019

14. Ojji DB, Opie LH et al. Relationship Between Left Ventricular Geometry and Soluble ST2 in a Cohort of Hypertensive Patients. J Clin Hypertens. 2013;15(12):899-904. DOI: 10.1111/jch.12205

15. Bartunek J, Delrue L, Van Durme F et al. Nonmyocardial Production of ST2 Protein in Human Hypertrophy and Failure Is Related to Diastolic Load. J Am College Cardiol. 2008;52(25):2166-74. DOI: 10.1016/j.jacc.2008.09.027

16. Lassus J, Gayat E, Mueller C et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: The Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013;168(3):2186-94. DOI: 10.1016/j.ijcard.2013.01.228

17. O’Meara E, Prescott M, Claggett B et al. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circulation: Heart Failure. 2018;11(5): e004446. DOI: 10.1161/circheartfailure.117.004446.

18. Бекетов В.Д., Лебедева М.В., Мухин Н.А. и др. Сурфактантные протеины A и D в диагностике идиопатического легочного фиброза и саркоидоза. Терапевтический архив. 2018;3(90):42-6. DOI: 10.26442/terarkh201890342-46

Beketov V.D., Lebedeva M.V., Mukhin N.A. et al. Clinical significance of the determination of surfactant proteins A and D in assessing the activity of lung sarcoidosis. Therapeutic archive. 2018;3(90):42-6. DOI: 10.26442/terarkh201890342-46 (in Russian).

19. Язев Е.Е., Лебедева М.В., Стрижаков Л.А. и др. Желудочковая экстрасистолия как редкий дебют саркоидоза. Клиническая медицина. 2017;95(12):1137-40. DOI: 10.18821/0023-2149-2017-95-12-1137-1140

Yazev E.E ., Lebedeva M.V., Strizhakov L.A., Pasha S. et al. Ventricular premature beats as a rare onset of sarcoidosis. Klin. med. 2017;95(12):1137-40. DOI: DOI: 10.18821/0023-2149-2017-95-12-1137-1140 (in Russian).

For citation:Lebedeva M.V., Strizhakov L.A., Beketov V.D., Taranova M.V. Clinical significance of determining sST2 in the blood of patients with cardiac sarcoidosis. Clinical review for general practice. 2024; 5 (1): 31–37 (In Russ.). DOI: 10.47407/kr2023.5.1.00357

All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.

Clinical review for general practice